title: Nevirapine plus didanosine: once or twice daily combination?
authors.forename: R P
authors.initials: RP
authors.lastname: van Heeswijk
authors.forename: A I
authors.initials: AI
authors.lastname: Veldkamp
authors.forename: J W
authors.initials: JW
authors.lastname: Mulder
authors.forename: P L
authors.initials: PL
authors.lastname: Meenhorst
authors.forename: F W
authors.initials: FW
authors.lastname: Wit
authors.forename: P
authors.initials: P
authors.lastname: Reiss
authors.forename: J M
authors.initials: JM
authors.lastname: Lange
authors.forename: M O
authors.initials: MO
authors.lastname: Kwakkelstein
authors.forename: J H
authors.initials: JH
authors.lastname: Beijnen
authors.forename: R M
authors.initials: RM
authors.lastname: Hoetelmans
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D016049:Didanosine / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000493:pharmacokinetics*
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine; D016049:Didanosine